2014 Breakthrough Prize Winners Announced

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The winners of the 2014 BREAKTHROUGH PRIZE in fundamental physics and life sciences were announced Dec. 12 at the NASA Ames Center, in Mountain View, Calif.

The prizes have a total awarded amount of $21 million.

The Breakthrough Prize in Life Sciencesrecognizes excellence in research aimed at curing intractable diseases and extending human life.

The 2014 recipients are:

  • James Allison, of MD Anderson Cancer Center, won for the discovery of T cell checkpoint blockade as an effective cancer therapy.
  • Robert Langer, the David H. Koch Institute Professor at the Massachusetts Institute of Technology, for discoveries leading to the development of controlled drug-release systems and new biomaterials.
  • Michael Hall, of the University of Basel, for the discovery of Target of Rapamycin and its role in cell growth control.
  • Alexander Varshavsky, of the California Institute of Technology, for discovering critical molecular determinants and biological functions of intracellular protein degradation.
  • Mahlon DeLong, of Emory University, for defining the interlocking circuits in the brain that malfunction in Parkinson’s disease. This scientific foundation underlies the circuit-based treatment of Parkinson’s disease by deep brain stimulation.
  • Richard Lifton, of Yale University and the Howard Hughes Medical Institute, for the discovery of genes and biochemical mechanisms that cause hypertension.

The Breakthrough Prize in Fundamental Physics recognizes transformative achievements in the field of fundamental physics, with a focus on recent developments.

The 2014 winners are Michael Green, of the University of Cambridge, and John Schwarz, of California Institute of Technology, for opening new perspectives on quantum gravity and the unification of forces.

YOU MAY BE INTERESTED IN

The tremendous promise—and potential peril—of the prostate-specific antigen (PSA) screening test have confounded guideline developers for decades. When introduced, PSA was one of the first and the only credible blood biomarkers for cancer screening. That a simple blood test should be used to screen for the most common cancer in men, one that was lethal for 3% of men and 5% of Black men, seemed like a slam dunk. 
With artificial intelligence becoming an increasingly ubiquitous part of the fabric of modern life, Cancer Grand Challenges has committed $10 million to a project aimed at developing AI “co-scientists”—AI agents that could help cancer researchers analyze data, generate hypotheses, and suggest new experiments.
For decades, cancer treatment has largely followed a familiar model: Identify the disease, determine its stage, and select the therapy most likely to benefit patients with similar characteristics. Even as targeted therapies and immunotherapies have transformed oncology, we have generally developed drugs for populations rather than individuals.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login